Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bardet-Biedl syndrome 4 protein (BBS4) is a structural, tetratricopeptide repeat domain-containing protein and a core component of the BBSome complex, which regulates protein trafficking to and from cilia in human cells. BBS4 plays a role in recruiting centriolar satellite proteins, organizing the microtubule and actin cytoskeleton, maintaining proteasomal integrity, and affecting cellular signaling and homeostasis, including mitochondrial function. Mutations in BBS4 can disrupt ciliary function and are causative for Bardet-Biedl syndrome, a multisystemic ciliopathy characterized by retinal degeneration, obesity, polydactyly, and renal anomalies. BBS4 is localized primarily at the basal body and cilium in cells. There are no approved drugs targeting BBS4, but it serves as a molecular biomarker for diagnosis and research into ciliopathy mechanisms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bardet-Biedl syndrome 4 protein (BBS4).